MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Changes in Inhibitory Control Differentiate Progressive Supranuclear Palsy from Early Parkinson’s Disease

B. Couto, F. Castano, J. Carrillo, M. Roca, A. Chade, O. Gershanik, G. Gomez-Arevalo (Buenos Aires, Argentina)

Meeting: 2025 International Congress

Keywords: Disinhibition, Executive functions, Progressive supranuclear palsy(PSP)

Category: MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales

Objective: To describe distinct type of errors and frequency of perseverative errors in executive, memory, language, and attentional tasks in PSP and PD.

Background: Progressive Supranuclear Palsy (PSP) and Parkinson’s Disease (PD) share overlapping cognitive and behavioral changes including attention and executive functioning resulting in challenging differential diagnosis at early disease stage. However, differences in inhibitory control may be the key to distinction within those cognitive domains.

Method: PSP and PD patients matched by disease duration and age were assessed with a neuropsychological battery including cognitive flexibility, memory, language, processing speed and performance on attentional tasks.

Results: 31 patients with PSP and 21 with PD were evaluated (PSP: 74.58±8.18 years; PD: 68.85±9.61 years), with no significant differences in age (U-Mann-Whitney =230; p=.07), in sex distribution (female: PSP: 54.8% vs PD: 33.3%; χ² = 2.33; p= .127). PSP patients exhibited significantly poorer performance in semantic verbal fluency (U-Mann-Whitney =131, p<.001), digit span (U-Mann-Whitney =79.5; p<.001), processing speed (T=-2.13; p=.04), memory encoding (U-Mann-Whitney =198; p=.02). A higher frequency of perseverative errors was found in PSP compared with PD (U-Mann-Whitney =32; p=.06). To account for attentional deficits, a General Attention Score was developed, enhancing the reliability of the observed differences.

Conclusion: The findings underscore the diagnostic value of perseverative errors in a set of tests used in routine neuropsychological assessments. Particularly, errors in tasks assessing cognitive flexibility and inhibitory control offer a valuable tool to early differentiation of PSP from early PD.

To cite this abstract in AMA style:

B. Couto, F. Castano, J. Carrillo, M. Roca, A. Chade, O. Gershanik, G. Gomez-Arevalo. Changes in Inhibitory Control Differentiate Progressive Supranuclear Palsy from Early Parkinson’s Disease [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/changes-in-inhibitory-control-differentiate-progressive-supranuclear-palsy-from-early-parkinsons-disease/. Accessed November 20, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/changes-in-inhibitory-control-differentiate-progressive-supranuclear-palsy-from-early-parkinsons-disease/

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley